ArticleBreast (Edinburgh, Scotland)2023
Axillary lymph node dissection: Dead or still alive?
Article in Breast (Edinburgh, Scotland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.Current oncology (Toronto, Ont.) · 2025Guideline
- Management of the Axilla After Neoadjuvant Chemotherapy: Can Axillary Needle Biopsy Replace Sentinel Node Biopsy?In vivo (Athens, Greece)Trial
- Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema.Annals of surgical oncology · 2026Article
- Prolongation of Postoperative Drainage Time in Indocyanine Green Lymphography as a Potential Marker for Lymphedema Development-A Prospective Pilot Study.Journal of clinical medicine · 2026Article
- Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.Breast cancer research and treatment · 2026Article
- Breast Cancer-Related Lymphedema: A Common Challenge among Nigerian Breast Cancer Survivors.Breast care (Basel, Switzerland) · 2026Article
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Nomogram for predicting axillary pathologic complete response in cN2-3 breast cancer after neoadjuvant chemotherapy.NPJ breast cancer · 2025Article
- Trends in Surgical Treatment for cT4 Breast Cancer After Neoadjuvant Systemic Therapy: A Nationwide Study in The Netherlands.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Equity in the Surgical Management of the Axilla.Annals of surgical oncology · 2025Article
- Characterizing Trends of Lymphedema After Axillary Lymph Node Dissection with and Without Immediate Lymphatic Reconstruction.Cancers · 2025Article
- Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study.Breast cancer (Tokyo, Japan) · 2025Article
- Sentinel lymph node detection for lung cancer surgery: a possible pathological surrogate of overall lymph node dissection.Frontiers in oncology · 2025Article
- Invasive lobular carcinoma of the breast: metastatic patterns and treatment modalities-a review.Frontiers in oncology · 2025Review
- Effect of the COVID-19 Pandemic on the Management of Breast Cancer Patients.Journal of clinical medicine · 2024Article
- A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.Breast cancer (Tokyo, Japan) · 2024Article
- An exploratory study of whether axillary lymph node dissection can be avoided in breast cancer patients with positive lymph nodes.Translational cancer research · 2024Article
- The prevalence of non-sentinel lymph node metastasis among breast cancer patients with sentinel lymph node involvement and its impact on clinical decision-making: a single-centred retrospective study.Oncology reviews · 2024Article
- Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.Therapeutic advances in medical oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although sentinel lymph node biopsy is now the primary method of axillary staging and is therapeutic for patients with limited nodal disease, axillary lymph node dissection (ALND) is still necessary for staging in groups where sentinel lymph node biopsy has not been proven to be accurate and to maintain local control in those with a heavy axillary tumor burden. Additionally, newer approaches to systemic therapy tailored to risk level sometimes necessitate knowledge of the number of involved axillary nodes which can only be obtained with ALND. Ongoing trials will address whether there are additional circumstances where radiotherapy can replace ALND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.